Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|JAK3 A572V||mature T-cell and NK-cell lymphoma||sensitive||JAK Inhibitor (Pan) - ATP competitive||Tofacitinib||Preclinical||Actionable||In a preclinical study, Xeljanz (tofacitinib), a pan-JAK inhibitor, reduced cell viability and increased apoptosis in a JAK3 A572V mutant natural killer/T-cell lymphoma cell line (PMID: 22705984).||22705984|
|JAK3 A572V||Advanced Solid Tumor||sensitive||JAK Inhibitor (Pan) - ATP competitive||Tofacitinib||Preclinical - Cell culture||Actionable||In a preclinical study, transformed human cells expressing JAK3 A572V in culture demonstrated decreased cell survival, increased G1 arrest, elevated apoptotic activity, and reduced phosphorylation of Stat5a when treated with Xeljanz (tofacitinib) (PMID: 21821710).||21821710|
|JAK3 A572V||acute myeloid leukemia||predicted - resistant||Ilginatinib||Preclinical - Cell culture||Actionable||In a preclinical study, an acute myeloid leukemia cell line harboring JAK3 A572V was insensitive to treatment with Ilginatinib (NS-018) in culture (PMID: 22829185).||22829185|